Skip to main content
Log in

Medikamentöse Therapie demenzieller Erkrankungen

Drug treatment of dementia

  • Schwerpunkt: Chronische Hirnerkrankungen
  • Published:
Der Internist Aims and scope Submit manuscript

Zusammenfassung

Demenzielle Syndrome nehmen weltweit vor allem aufgrund der demografischen Entwicklung zu. Die frühe Diagnostik und individualisierte Therapie bieten die Chance auf Heilung bei sekundären Demenzen. Bei primären neurodegenerativen Formen bieten sie vor allem die Möglichkeit, den Verlauf zu verbessern. Im Rahmen eines multimodalen Managements umfasst die Therapie von Demenzerkrankungen die medikamentöse Behandlung, nichtmedikamentöse Therapiestrategien und psychosoziale Interventionen. Die Behandlung erfolgt in Abhängigkeit von Demenzform und Stadium. Eine leitliniengerechte antidementive Medikation und die differenzierte medikamentöse Therapie der häufigen psychischen und Verhaltenssymptome tragen entscheidend dazu bei, Lebensqualität und alltagsrelevante Fähigkeiten zu stabilisieren, die Progression zu verzögern und damit die Versorgungssituation der Erkrankten und ihrer Angehörigen zu verbessern.

Abstract

The number of patients with dementia continues to increase worldwide, mainly due to the demographic developments. Early diagnosis and individualized therapy offers the chance of healing in secondary dementias. The therapy of the more common primary neurodegenerative forms is able to improve the course of the disease. As part of a multimodal management the therapy of dementias includes pharmacological treatment, nondrug treatment strategies, and psychosocial interventions. The treatment is administered depending on dementia form and stage. Antidementive medication and differentiated pharmacological therapy of frequent mental and behavioral symptoms corresponding to current guidelines contribute decisively to stabilize quality of life and activities of daily living, delaying the progression, and thus improving the care situation of patients and caregivers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Abb. 1

Literatur

  1. Schäufele M et al (2013) Prävalenz von Demenzen und ärztliche Versorgung in deutschen Pflegeheimen: eine bundesweite repräsentative Studie. Psychiatr Prax 40(4):200–206

    Article  PubMed  Google Scholar 

  2. Hibbeler B (2015) Demenz: Weltweit fast 10 Millionen Neuerkrankungen. Dtsch Ärztebl 112(37):A1470

  3. Holt S, Schmiedl S, Thürmann PA (2010) Potenziell inadäquate Medikation für ältere Menschen: Die PRISCUS-Liste. Dtsch Arztebl Int 107:543–551

    PubMed  PubMed Central  Google Scholar 

  4. http://www.awmf.org/uploads/tx_szleitlinien/038-013l_S3-Demenzen-2016-07.pdf. Zugegriffen: 12. Okt. 2016

  5. Lopez OL et al (2009) Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatr 80:600f

    Article  Google Scholar 

  6. Tariot PN et al (2004) Memantine treatment in patients with moderate to severe Alzheimer disease already receiving Donepezil: a randomized controlled trial. J Am Med Assoc 291(3):317–324

    Article  CAS  Google Scholar 

  7. van Dyck CH, Schmitt FA, Olin JT et al. (2006) A responder analysis of memantine treatment in patients with Alzheimer disease maintained an donepezil. Am J Geriatr Psychiatry 14:428–437

  8. Zhu CW et al (2006) Economic considerations in the management of Alzheimer’s disease. Clin Interv Aging 1(2):143–154

    Article  PubMed  PubMed Central  Google Scholar 

  9. Brodaty H et al (2003) Behavioural and psychological symptoms of dementia: a seven-tiered model of service delivery. Med J Aust 178(5):231–234

    PubMed  Google Scholar 

  10. Wang PS et al (2005) Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 353(22):2335–2341

    Article  CAS  PubMed  Google Scholar 

  11. Yang G, Wang Y, Sun J, Zhang K, Liu J (2016) Ginkgo Biloba for mild cognitive impairment and Alzheimer’s disease: a systematic review and meta-analysis of randomized controlled trials. Curr Top Med Chem 16(5):520–528

    Article  CAS  PubMed  Google Scholar 

  12. Gauthier S, Schlaefke S (2014) Efficacy and tolerability of Ginkgo biloba extract EGb 761® in dementia: a systematic review and meta-analysis of randomized placebo-controlled trials. Clin Interv Aging 9:2065–2077

    Article  PubMed  PubMed Central  Google Scholar 

  13. Wang J, Yu JT, Wang HF, Meng XF, Wang C, Tan CC, Tan L (2015) Pharmacological treatment of neuropsychiatric symptoms in Alzheimer’s disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatr 86(1):101–109

    Article  PubMed  Google Scholar 

  14. Leong C (2014) Antidepressants for depression in patients with dementia: a review of the literature. Consult Pharm 29(4):254–263

    Article  PubMed  Google Scholar 

  15. Cummings J, Aisen PS, DuBois B, Frölich L, Jack CR Jr, Jones RW, Morris JC, Raskin J, Dowsett SA, Scheltens P (2016) Drug development in Alzheimer’s disease: the path to 2025. Alzheimers Res Ther 8:39

    Article  PubMed  PubMed Central  Google Scholar 

  16. Harrison F, Aerts L, Brodaty H (2016) Apathy in dementia: systematic review of recent evidence on pharmacological treatments. Curr Psychiatry Rep 18(11):103

    Article  PubMed  Google Scholar 

  17. Schneider LS, Mangialasche F, Andreasen N, Feldman H, Giacobini E, Jones R, Mantua V, Mecocci P, Pani L, Winblad B, Kivipelto M (2014) Clinical trials and late-stage drug development for Alzheimer’s disease: an appraisal from 1984 to 2014. J Intern Med 275(3):251–283

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Laver K, Dyer S, Whitehead C, Clemson L, Crotty M (2016) Interventions to delay functional decline in people with dementia: a systematic review of systematic reviews. BMJ Open 6(4):e010767

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J. W. Kraft.

Ethics declarations

Interessenkonflikt

J.W. Kraft gibt an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine vom Autor durchgeführten Studien an Menschen oder Tieren.

Additional information

Redaktion

C. Sieber, Nürnberg

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kraft, J.W. Medikamentöse Therapie demenzieller Erkrankungen. Internist 58, 117–124 (2017). https://doi.org/10.1007/s00108-016-0180-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00108-016-0180-1

Schlüsselwörter

Keywords

Navigation